Proton Pump Inhibitors PPIs Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Vonoprazan: A Review in Helicobacter pylori Infection
AbstractTreatment for the eradication ofHelicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna®) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Fol...
Source: Drugs - February 23, 2024 Category: Drugs & Pharmacology Source Type: research

A Population-Based Study on the Incidence, Risk Factors, and Outcome of Salmonella Bloodstream Infections in South Sweden 2012 –2022
ConclusionInvasiveSalmonella infections are rare in South Sweden. In a cohort of enteric and invasiveSalmonella infection, the absence of classic gastroenteritis symptoms increases the risk ofSalmonella bloodstream infection. This study highlights the importance of distinguishing between clinical presentations to guide appropriate treatment whenSalmonella infection is suspected. The declining trend in incidence, particularly associated with international travel, necessitates further investigation to understand contributing factors. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 23, 2024 Category: Infectious Diseases Source Type: research

Interaction Between Tacrolimus and Proton Pump Inhibitor in a Kidney Transplant Recipient
Exp Clin Transplant. 2024 Jan;22(Suppl 1):354-355. doi: 10.6002/ect.MESOT2023.P89.ABSTRACTWe aimed to present a drug monitoring profile of tacrolimus and proton pump inhibitor coadministration in a 23-year-old male patient with a history of high blood pressure who underwent kidney transplant. The patient's serum trough levels of tacrolimus were in the therapeutic range until omeprazole 20 mg daily was prescribed. Tacrolimus trough serum level increased to 29.5 ng/mL under the same daily dose and to 13.9 ng/mL after tacrolimus daily dose was decreased to 6 mg/day. This increase in tacrolimus serum level was behind a renal f...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Khouloud Ferchichi Syrine Ben Hammamia Mouna Ben Sassi Hanene El Jebari Rim Charfi Riadh Daghfous Emna Gaies Sameh Trabelsi Source Type: research

Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and < em > Helicobacter pylori < /em >
Postgrad Med. 2024 Feb 22. doi: 10.1080/00325481.2024.2320081. Online ahead of print.ABSTRACTGastroesophageal reflux disease (GERD) and Helicobacter pylori infection are different disease states that are united by the core role of acid suppression in their management. In GERD, proton pump inhibitors (PPIs) have long been standard therapy based on abundant positive clinical trial data supporting their efficacy and safety. In H. pylori, PPIs are also a critical element of therapy in combination with 1 or more antibiotics to achieve and maintain a pH that maximizes the efficacy of therapy. Despite the considerable clinical su...
Source: Postgraduate Medicine - February 22, 2024 Category: Internal Medicine Authors: Carol M Antequera Kimberly Orleck Rinu Jacob Amy Kenneally Wendy L Wright Source Type: research